New Erectile Dysfunction Treatment Likely to Face Stiff Competition If Approved
The demand for drugs to treat erectile dysfunction has risen to meet the needs of an aging population and to help combat disease-related causes.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 116
Nektar Therapeutics and Pfizer Team Up in Cancer Collaboration
Nektar shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer to evaluate several combination regimens in multiple cancer settings.
4 States Voting on Marijuana Legalization Efforts This Tuesday
Four states have marijuana legalization efforts of sorts up for grabs on Tuesday, November 6, 2018. Here is some basic information on the efforts.
Eli Lilly Dips Despite Solid Q3 Results
Eli Lilly released better-than-expected third-quarter financial results before the markets opened on Tuesday.
Why Regulus Therapeutics Is Booming
Regulus Therapeutics shares shot up on Tuesday after the company announced that it had amended and restructured its collaboration and license agreement with Sanofi.
CVS Earnings, Merger With Aetna Look Good to Investors
CVS reported third-quarter results Tuesday morning that beat estimates on both the top and bottom lines. The company also said it expects to close its acquisition of Aetna by Thanksgiving.
What Drove Mylan Earnings in Q3
Mylan reported better-than-expected quarterly results late Monday, and shares rose sharply in Friday's premarket.
Vapotherm Gears Up for IPO
Medical technology company Vapotherm intends to price 4 million shares for and initial public offering valued up to more than $73 million.
What to Watch For When Eli Lilly Reports Tuesday Morning
Eli Lilly is scheduled to release its most recent quarterly results before the markets open on Tuesday.
Why Clearside Biomedical Shares Were Halved
Clearside Biomedical shares were halved early on Monday after the firm reported results from its late-stage Sapphire trial.
AbbVie Little Changed Despite Big Bottom-Line Beat
AbbVie released its third quarter financial results before the markets opened on Friday. The pharma giant said that it had $2.14 in earnings per share (EPS) and $8.24 billion in revenue, compared with consensus…
Why the FDA Is Dragging Alkermes Down
Alkermes shares dropped early on Friday after the company anncounced the results from its most recent meeting with the U.S. Food and Drug Administration.
The Drag on Teva’s Q3 Results
Teva Pharmaceutical released its most recent earnings report before the markets opened on Thursday.
KemPharm Lands New License Deal for Apadaz
KemPharm shares made a handy gain on Wednesday after the firm announced a new license agreement with KVK Tech for the U.S. commercial rights of its FDA-approved prodrug product, Apadaz.
Acadia Pharma Slides Despite Positive Major Depressive Disorder Results
Acadia Pharmaceuticals shares dipped on Wednesday despite announcing positive top-line results from its Clarity mid-stage study in major depressive disorder (MDD).